Speaker: Stuart Grieve, MB BS, BSc, DPhil(oxon), Dir. of Imaging, Charles Perkins Centre & Brain Dynamics Centre
The iSPOT-D study aims to look for biomarkers that can predict outcomes from treatment with common anti-depressant medications (ADM). There are currently no clinically useful pre-treatment measures can guide choice of therapy in depression. Using functional and structural MRI we have characterized key abnormalities that distinguish a depressed state, including network level maps of abnormal connectivity involving the amygdala, anterior cingulate and prefrontal cortex. Using this data we have developed novel MRI metrics that can not only predict response/remission in depression, but can also identify individuals that will not remit to ADM treatment with a high degree of sensitivity.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?